Viking Therapeutics to Report Financial Results for Second Quarter 2020 on July 29, 2020

Viking Therapeutics (VKTX) announced it will release its financial results for Q2 2020 on July 29, 2020, after market close.

Rhea-AI Summary

Viking Therapeutics (VKTX) announced it will release its financial results for Q2 2020 on July 29, 2020, after market close. The company will host a conference call at 4:30 PM ET to discuss the results and corporate updates. Stakeholders can join via phone or listen online. Viking Therapeutics focuses on developing innovative therapies for metabolic and endocrine disorders, with ongoing clinical programs including VK2809 for NASH and VK5211 for hip fracture recovery. The company holds five therapeutic programs licensed from Ligand Pharmaceuticals.

Positive

• VK2809 demonstrated statistically significant reductions in LDL-C and liver fat in Phase 2 trials.
• VK5211 showed significant improvements in lean body mass for patients recovering from hip fractures.

Negative

• None.

Argus Session date unavailable

-0.88% session move Open Argus

Details

News Market Reaction – VKTX

The recorded move for VKTX in the trading session of this news was -0.88%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, July 22, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2020, after the market close on Wednesday, July 29, 2020.

The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 29, 2020.  To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until August 5, 2020 by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering conference ID #10145659.  Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.

About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.  Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.  In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.  The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD). 

Viking's other programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator.  In a Phase 2 trial in patients recovering from hip fracture, patients who received VK5211 experienced significant improvements in measures of lean body mass compared with patients who received placebo.  Other programs also include VK0612, a first-in-class, orally available drug candidate in Phase 2 development for the treatment of type 2 diabetes as well as two earlier-stage programs targeting metabolic diseases and anemia.  The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

View original content to download multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-second-quarter-2020-on-july-29-2020-301098154.html

SOURCE Viking Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Viking Therapeutics report its Q2 2020 financial results?

Viking Therapeutics will report its Q2 2020 financial results on July 29, 2020.

What time is the Viking Therapeutics conference call on July 29, 2020?

The conference call is scheduled for 4:30 PM ET on July 29, 2020.

What is the focus of Viking Therapeutics' clinical programs?

Viking Therapeutics focuses on developing therapies for metabolic and endocrine disorders, with programs like VK2809 for NASH.

What were the results of VK2809 in clinical trials?

VK2809 showed statistically significant reductions in LDL-C and liver fat content in Phase 2 trials.

What improvements did VK5211 show in clinical trials?

VK5211 demonstrated significant improvements in measures of lean body mass in patients recovering from hip fractures.